Skip to main content

Advertisement

SpringerLink
Log in

ASO Author Reflections: Inflammatory Breast Cancer: Durable Breast Cancer-Specific Survival for HER2-Positive Patients with a Pathologic Complete Response to Neoadjuvant Therapy

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, et al. Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: A large population-based study. Cancer. 2011;117:1819–26.

    Article  PubMed  Google Scholar 

  2. Kupstas AR, Hoskin TL, Day CN, Boughey JC, Habermann EB, Hieken TJ. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database. Br J Surg. 2020;107(8):1033–41.

    Article  CAS  PubMed  Google Scholar 

  3. Hieken TJ, Boughey JC, Degnim AC, Glazebrook KN, Hoskin TL. Inflammatory breast cancer: Durable breast cancer-specific survival for HER2-positive patients with a pathologic complete response to neoadjuvant therapy. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-12037-7.

    Article  PubMed  Google Scholar 

  4. Leon-Ferre RA, Hieken TJ, Boughey JC. The Landmark Series: Neoadjuvant chemotherapy for triple-negative and HER2-positive breast cancer. Ann Surg Oncol. 2021;28(4):2111–9. https://doi.org/10.1245/s10434-020-09480-9.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA

    Tina J. Hieken MD

  2. Department of Quantitative Health Sciences, Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA

    Tanya L. Hoskin MS

Authors
  1. Tina J. Hieken MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tanya L. Hoskin MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tina J. Hieken MD.

Ethics declarations

Disclosure

Tina J. Hieken MD has unrelated research funding from SkylineDX BV and Genentech. Tanya L. Hoskin has no disclosures to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hieken, T.J., Hoskin, T.L. ASO Author Reflections: Inflammatory Breast Cancer: Durable Breast Cancer-Specific Survival for HER2-Positive Patients with a Pathologic Complete Response to Neoadjuvant Therapy. Ann Surg Oncol 29 (Suppl 3), 597–598 (2022). https://doi.org/10.1245/s10434-022-12181-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-022-12181-0

Search

Navigation